Stay updated on Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe ClinicalTrials.gov record for the pembrolizumab and idelalisib lung cancer study is displayed, including its terminated status, eligibility criteria, treatment plan, and outcomes.SummaryDifference50%

- Check15 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.2 to v3.8.0, while the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide NIH notice announces that federal agencies are transitioning to the term “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check29 days agoChange DetectedThe site footer revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check36 days agoChange DetectedThe error page’s footer revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden message.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the trial's study details with an access-denied message. As a result, users cannot view the essential information about the NCT03257722 study on this page.SummaryDifference18%

Stay in the know with updates to Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.